Are the Second-generation Antipsychotics Cost-effective? A Critical Review on the Background of Different Health Systems

Background: Method: Results: Conclusion:

[1]  S. Frangou,et al.  Service use and costs of treating schizophrenia with atypical antipsychotics. , 2001, The Journal of clinical psychiatry.

[2]  M. Drummond,et al.  The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia , 2001, European Psychiatry.

[3]  S. Woods,et al.  Consistency of atypical antipsychotic superiority to placebo in recent clinical trials , 2001, Biological Psychiatry.

[4]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[5]  Nancy H. Covell,et al.  Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. , 2000, Archives of general psychiatry.

[6]  D. Revicki,et al.  P02.317 Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia , 2000, European Psychiatry.

[7]  B. Kinon,et al.  Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  R. Branch,et al.  Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. , 1999, The Journal of clinical psychiatry.

[9]  J. Pierson,et al.  Economic Evaluation of Risperidone in an Outpatient Population , 1999, The Annals of pharmacotherapy.

[10]  K. Griffiths,et al.  Clozapine in Community Practice: A 3-Year Follow-Up Study in the Australian Capital Territory , 1999, The Australian and New Zealand journal of psychiatry.

[11]  C. Pen,et al.  An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France , 1999, Schizophrenia Research.

[12]  R. Rosenheck,et al.  Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1999, Archives of general psychiatry.

[13]  A. Rush,et al.  Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. , 1999, Clinical therapeutics.

[14]  A. Altamura,et al.  Health care costs of therapy‐refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy , 1999, Acta psychiatrica Scandinavica.

[15]  D. Revicki.  Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia , 1999, Schizophrenia Research.

[16]  J. Schulenburg,et al.  Die direkten und indirekten Kosten der Schizophrenie , 1999 .

[17]  S. Leucht,et al.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials , 1999, Schizophrenia Research.

[18]  R. Conley,et al.  Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  K. Hawkins,et al.  Health status and health care costs for publicly funded patients with schizophrenia started on clozapine. , 1998, Psychiatric services.

[20]  D. Luchins,et al.  Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. , 1998, Psychiatric Services.

[21]  K. Goa,et al.  Risperidone. A pharmacoeconomic review of its use in schizophrenia. , 1998, PharmacoEconomics.

[22]  F. Goodwin,et al.  Cost-effectiveness of clozapine therapy for severe psychosis. , 1998, Psychiatric services.

[23]  W. Reid,et al.  Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. , 1998, The Journal of clinical psychiatry.

[24]  M. Stevens,et al.  Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. , 1998, Clinical therapeutics.

[25]  B. Lawrence,et al.  Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. , 1998, The American journal of managed care.

[26]  D. Thompson.  Cost of Switching from Neuroleptics to Risperidone and Clozapine , 1997 .

[27]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[28]  L. Mechling,et al.  Impact of risperidone on the use of mental health care resources. , 1997, Psychiatric services.

[29]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[30]  D. Keegan,et al.  Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy , 1996 .

[31]  D. Jonsson,et al.  Cost‐effectiveness of clozapine treatment in therapy‐refractory schizophrenia , 1995, Acta psychiatrica Scandinavica.

[32]  M. Toprac,et al.  Savings in hospital bed-days related to treatment with clozapine. , 1994, Hospital & community psychiatry.

[33]  G. Honigfeld,et al.  A two-year clinical and economic follow-up of patients on clozapine. , 1990, Hospital & community psychiatry.

[34]  Ruth E. Brown,et al.  Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. , 1990, Hospital & community psychiatry.

[35]  D. Revicki.  Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. , 2001, Current opinion in investigational drugs.

[36]  K. Wahlbeck,et al.  Clozapine versus typical neuroleptic medication for schizophrenia. , 2000, The Cochrane database of systematic reviews.

[37]  D. Revicki,et al.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. , 1999, PharmacoEconomics.

[38]  P. Neumann.  Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. , 1999, The Journal of clinical psychiatry.

[39]  S. Tunis,et al.  Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. , 1999, The Journal of clinical psychiatry.

[40]  J. Sacristán,et al.  Pharmacoeconomic Assessment of Olanzapine in the Treatment of Refractory Schizophrenia Based on a Pilot Clinical Study , 1998, Clinical drug investigation.

[41]  B. Lawrence,et al.  Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. , 1998, Psychopharmacology bulletin.

[42]  P. Finley,et al.  Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. , 1998, Psychopharmacology bulletin.

[43]  H. Robert,et al.  Evaluation médico-économique du traitement par la clozapine versus les traitements neuroleptiques antérieurs , 1997 .

[44]  W. Hargreaves,et al.  Clozapine's cost effectiveness. , 1995, The American journal of psychiatry.

[45]  C. Gury,et al.  Leponex® : l'expérience du pharmacien hospitalier , 1995 .

[46]  B. Snitz,et al.  Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. , 1993, The American journal of psychiatry.